Tianjin Medical Journal

Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (11): 1209-1212.doi: 10.11958/20220383

• Drug Clinical Evaluations • Previous Articles     Next Articles

Postoperative analgesic effect of intravenous flurbiprofen axetil combined with nalbuphine in patients undergoing orbital decompression

CHEN Yiren1(), ZHENG Yajing1, CHEN Ying2   

  1. 1 Department of Anesthesiology, Hainan Eye Hospital, Zhongshan Ophthalmic Center, Sun Yat-sen University, Haikou 570311, China
    2 Department of Anesthesiology, Zhongshan Ophthalmic Center, Sun Yat-sen University
  • Received:2022-03-14 Revised:2020-05-20 Published:2022-11-15 Online:2022-11-11

RichHTML

2

PDF (PC)

1786

Abstract:

Objective To evaluate the postoperative analgesic effect of intravenous flurbiprofen axetil combined with nalbuphine in patients undergoing orbital decompression. Methods A total of 120 patients who planned to undergo orbital decompression in our hospital were included. Patients were randomly divided into the flurbiprofen group (F group), the nalbuphine group (N group) and the flurbiprofen combined nalbuphine group (F+N group) with 40 patients in each group. All patients were given analgesic drugs intravenously immediately after the operation. Patients in the F group were intravenously injected 100 mg flurbiprofen axetil, patients in the N group were intravenously injected with nalbuphine 0.1 mg/kg and patients in the F+N group were intravenously injected with flurbiprofen axetil 100 mg and nalbuphine 0.1 mg/kg. The Numerical Rating Scale (NRS) and Ramsay sedation score were used to evaluate pain and sedation of patients in the three groups immediately after returning to ward (T0), 2 h (T2) and 12 h (T12) after surgery. Adverse reactions including the incidence of hypotension, nausea, vomiting, shivering, respiratory depression and pruritus were recorded within 24 hours of operation. Results A total of 116 patients were eventually enrolled, including 38 patients in the F group, 38 patients in the N group and 40 patients in the F+N group, respectively. NRS scores at T0 and T2 were significantly lower in the F+N group than those in the F group and the N group (P<0.05). There was no significant difference in NRS score at T12 between the three groups (P>0.05). There were no significant differences in Ramsay sedation scores at T0, T2 and T12 between the 3 groups (P>0.05). In terms of adverse reactions, there were no significant differences in the incidence of hypotension, nausea, vomiting, shivering, respiratory depression and pruritus between the three groups (P>0.05). Conclusion Intraoperative intravenous flurbiprofen axetil combined with nalbuphine can provide better postoperative analgesic effect and higher safety for patients undergoing orbital decompression.

Key words: Graves ophthalmopathy, nalbuphine, flurbiprofen axetil, orbital decompression, postoperative analgesia

CLC Number: